Suppr超能文献

颅内非海绵窦良性脑膜瘤的立体定向放射外科治疗:国际立体定向放射外科学会系统评价、荟萃分析和实践指南。

Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline.

机构信息

Department of Neurosurgery, Unit of Radiotherapy, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italia.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.

出版信息

Neurosurgery. 2020 Oct 15;87(5):879-890. doi: 10.1093/neuros/nyaa169.

Abstract

BACKGROUND

Stereotactic radiosurgery (SRS) for benign intracranial meningiomas is an established treatment.

OBJECTIVE

To summarize the literature and provide evidence-based practice guidelines on behalf of the International Stereotactic Radiosurgery Society (ISRS).

METHODS

Articles in English specific to SRS for benign intracranial meningioma, published from January 1964 to April 2018, were systematically reviewed. Three electronic databases, PubMed, EMBASE, and the Cochrane Central Register, were searched.

RESULTS

Out of the 2844 studies identified, 305 had a full text evaluation and 27 studies met the criteria to be included in this analysis. All but one were retrospective studies. The 10-yr local control (LC) rate ranged from 71% to 100%. The 10-yr progression-free-survival rate ranged from 55% to 97%. The prescription dose ranged typically between 12 and 15 Gy, delivered in a single fraction. Toxicity rate was generally low.

CONCLUSION

The current literature supporting SRS for benign intracranial meningioma lacks level I and II evidence. However, when summarizing the large number of level III studies, it is clear that SRS can be recommended as an effective evidence-based treatment option (recommendation level II) for grade 1 meningioma.

摘要

背景

立体定向放射外科(SRS)治疗良性颅内脑膜瘤已得到广泛认可。

目的

代表国际立体定向放射外科协会(ISRS)对相关文献进行总结,为良性颅内脑膜瘤的 SRS 治疗提供循证实践指南。

方法

系统性检索了 1964 年 1 月至 2018 年 4 月发表的关于 SRS 治疗良性颅内脑膜瘤的英文文献,检索范围涵盖 3 个电子数据库(PubMed、EMBASE 和 Cochrane 中央注册库)。

结果

在总共检索到的 2844 篇文献中,有 305 篇文献全文符合纳入标准,27 篇文献最终被纳入本分析。除 1 篇外,其余均为回顾性研究。10 年局部控制率为 71%至 100%,无进展生存率为 55%至 97%。处方剂量通常为 12 至 15Gy,单次分割。总体而言,毒性发生率较低。

结论

目前关于 SRS 治疗良性颅内脑膜瘤的文献主要为 III 级证据,缺乏 I 级和 II 级证据。但在对大量 III 级研究进行总结后,我们可以明确 SRS 是 1 级脑膜瘤的一种有效治疗选择(推荐级别 II)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba64/7566438/56235d646f61/nyaa169fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验